Myeloma risk prediction is strong, but matching each patient to optimal therapy is still being tested, says Nikhil C. Munshi, ...
The proposal would bar common ownership of insurers or PBMs with medical providers or management services organizations, aiming to eliminate vertically integrated steering and self-dealing incentives.
Weill Cornell's Mateo Mejia Saldarriaga, MD, explains why oral options like iberdomide and clinical trials matter in the immunotherapy era of myeloma.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates ...
SMART-MASH found about a third more patients with cirrhosis than Agile 4 while using costly fibrosis tests in only some ...
Phase 3 Viti-Up trials show Rinvoq (upadacitinib) JAK inhibitor boosts facial and body repigmentation in nonsegmental ...
Started at advanced fibrosis or cirrhosis, pegozafermin lowered liver collagen below baseline and prevented liver cancer in a ...
ETNK1 fusion in MDS/MPN with eosinophilia; the fusion disappeared when disease relapsed as AML after transplant.
A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven ...
Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at ...
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and ...
Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results